Israel’s vaccine against the deadly Covid-19 virus will begin human trials by the end of the month.

The vaccine’s developer, the Israel Institute for Biological Research (IIBR), has named the potential life-saver Brilife. It is a combination of the Hebrew word for health, “bri’ut,” Israel’s domain name, “il,” and “life.”

“We are at a very significant moment,” Defense Minister Benny Gantz said after visiting the research center. “Prof. Shapira and the entire [IIBR] team have done fantastic work. They are the scientific vanguard of the State of Israel and they have brought this vaccine to the stage where we can soon begin trials on human beings.”

“If this process succeeds, it will be great news for the State of Israel and maybe for all nations of the world,” he added.

Israel’s contender for the most sought-after vaccine in the world is behind four pharmaceutical giants, three American and one British, that have already begun Phase 3 trials with tens of thousands of volunteers. There are also five vaccines reportedly being mass-tested in China and one in Russia.

Third-stage testing is the final step before regulatory approval.